Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai receives research approval

Eisai receives research approval

4th April 2008

Eisai Medical Research has been given the approval to move ahead with clinical trials of a new treatment for Alzheimer’s disease.

According to PharmaLive.com the pharmaceutical company has been given the backing of the US Food and Drug Administration this week – meaning its testing of the E2012 compound can go ahead.

It is hoped that the new research will result in a “next generation Alzheimer’s disease treatment”, following the suspension of its Phase I studies in February 2007.

The company claims that the need for new drugs to help combat Alzheimer’s is increasing and that the E2012 novel compound could suppresses the production of beta-amyloid – thought to be a causes of the disease.

Eisai said in a recent statement: “the company is committed to contributing to increasing the benefit to Alzheimer’s disease patients and their families”.

Recent research featured in the Journal of Neuroinflammation suggested one cup of coffee per day could reduce the possibility of Alzheimer’s development, Science Daily reports.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.